ArticleSmall (Weinheim an der Bergstrasse, Germany)2025
Tracker Nanocatalyst for Screening of Intracellular Copper-Catalyzed Azide-Alkyne Cycloadditions.
Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tracker Nanocatalyst for Screening of Intracellular Copper-Catalyzed Azide-Alkyne Cycloadditions.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Intracellular copper-catalyzed azide-alkyne cycloaddition (CuAAC) offers immense potential for bioorthogonal chemistry, but its application is severely hindered by copper toxicity and the challenge of controlling catalysis within the complex cellular environment. Heterogeneous copper catalysts can reduce toxicity by minimizing free copper exposure and enabling localized activity, yet optimizing their performance in situ within living cells remains a significant hurdle. Here, the development of a novel dual-functional nanocatalyst, Cu@BTTAA-Cy5-NPs, that combines robust heterogeneous CuAAC catalytic activity with intrinsic fluorescence tracking is reported. The successful synthesis and characterization of these monodispersed nanoparticles is demonstrated, confirming efficient copper loading stabilized by BTTAA and the nanoparticle matrix, and critically, the retention of Cy5 fluorescence for tracking. This unique dual functionality allows for real-time monitoring of nanoparticle localization and correlation with catalytic product formation via distinct fluorescence channels, enabling, for the first time to our knowledge, comprehensive in situ screening and optimization of CuAAC reaction conditions directly within living cells using fluorescence feedback. The nanoparticles exhibit excellent biocompatibility and cellular uptake, showing no significant toxicity, apoptosis, or oxidative stress at active concentrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.